Category: News

Home / News
Meet the Expert at ESMO 2018
Post

Meet the Expert at ESMO 2018

Heading to Germany? The European Society for Medical Oncology is the leading European professional organisation for medical oncology. The ESMO congress 2018 will take place in Munich, Germany from 19 Oct to 23 Oct, under the tagline ‘Securing access to optimal cancer care’. This is a multi-professional platform for oncology education and exchange and for...

New research reveals certain mutations detected by plasma genotyping in NSCLC patients due to clonal haematopoiesis, not tumour
Post

New research reveals certain mutations detected by plasma genotyping in NSCLC patients due to clonal haematopoiesis, not tumour

The large amount of enthusiasm behind the potential applications of plasma cell-free DNA (cfDNA) analysis appears to have outpaced our biological understanding of this new method. Plasma cfDNA is a complex mixture derived from germline, foetal, infectious and malignant sources, and its analysis is increasingly becoming adopted as a method for non-invasive genotyping of advanced...

New research highlights superior clinical benefit and lower utility cost of Caris Molecular Intelligence
Post

New research highlights superior clinical benefit and lower utility cost of Caris Molecular Intelligence

New research1 presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) from 4th-8th November 2017 in Glasgow, Scotland has compared the clinical benefit and utility cost of Caris Molecular Intelligence (CMI), FoundationOne (FMI) and Paradigm (PCDx). The research found that 34% of patients profiled with Caris Molecular Intelligence had clinical benefit when compared...

New research compares Caris Molecular Intelligence and Foundation One-guided treatment costs
Post

New research compares Caris Molecular Intelligence and Foundation One-guided treatment costs

New research1 presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting from 4th-8th November 2017 in Glasgow, Scotland has shown the impact of profiling with Caris Molecular Intelligence, which changes treatment decisions in 88% of cases. The research also revealed the far lower treatment costs per patient per cycle using Caris Molecular...

New research from ESMO highlights clinical benefit of Caris Molecular Intelligence
Post

New research from ESMO highlights clinical benefit of Caris Molecular Intelligence

The progression-free survival (PFS) of patients with heavily pre-treated rare or refractory cancer usually declines with every new line of therapy. However, new research presented at the European Society for Medical Oncology (ESMO) 2017 Congress has shown a one month increase in PFS in these patients when treated with Caris Molecular Intelligence–guided treatment compared to...

NICE briefing on Caris Molecular Intelligence
Post

NICE briefing on Caris Molecular Intelligence

The National Institute for Health and Care Excellence (NICE) has released a medical technology innovation briefing on Caris Molecular Intelligence (CMI) for guiding cancer treatment. NICE provides national guidance on improving healthcare in the United Kingdom. The medtech innovation briefing is designed to help the National Healthcare Service and social care commissioners and staff who are...

Molecular profiling explained by Dr David Spetzler: An interview
Post

Molecular profiling explained by Dr David Spetzler: An interview

NH: Hello and thank you for tuning into the program. I’m your host Neil Howard here on Health Professional Radio. Our guest today is Chief Scientific Officer at Caris Life Sciences, joining us here today to talk about his company’s involvement with several studies where cancer is being treated based on its molecular profile rather...

Guardant Health files lawsuit against Foundation Medicine
Post

Guardant Health files lawsuit against Foundation Medicine

An original complaint against Foundation Medicine Inc. has recently been filed by Guardant Health Inc. Guardant seeks to recover damages and other relief and an order to stop FMI from making false and misleading statements about the performance of FMI’s assays, as well as other assays, in its advertising. Reference Guardant Health Complaint. 2017.

First results from the AURORA pilot study for molecular screening of patients with advanced breast cancer
Post

First results from the AURORA pilot study for molecular screening of patients with advanced breast cancer

In April 2014, OncoDNA, a clinical NGS provider affiliated with the Institute of Pathology and Genetics in Gosselies, Belgium, announced that it was providing targeted sequencing of metastatic breast cancer patients for a large international effort called AURORA, led by the Breast International Group, a non-profit organisation that facilitates breast cancer research. As the testing...

Measuring prevalence of oncogenic homologous recombination pathway mutations across 53,000 tumours
Post

Measuring prevalence of oncogenic homologous recombination pathway mutations across 53,000 tumours

Results of a molecular profiling analysis to identify the frequency of Homologous Recombination Deficiencies (HRD) from approximately 53,000 tumours have been announced. The results demonstrated the utility of the company’s proprietary Caris Molecular Intelligence® Comprehensive Genomic Profiling Plus (CGP+) platform for use in personalised medicine and drug discovery and development. The study was presented at...